Sign In
Buy AXSM
$233.49
+11.33 (+5.10%)
At Close: Jun 03, 2026
SG Americas Securities LLC Acquires 5,584 Shares of Axsome Therapeutics, Inc. $AXSM
05:28am, Saturday, 04'th Apr 2026
SG Americas Securities LLC lifted its holdings in shares of Axsome Therapeutics, Inc. (NASDAQ: AXSM) by 46.2% during the fourth quarter, according to the company in its most recent Form 13F filing wit
Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From Now
05:24pm, Wednesday, 25'th Mar 2026
Summit Therapeutics shares could drop later this year if it doesn't earn approval for its leading candidate. Madrigal Pharmaceuticals and Axsome Therapeutics could move in the opposite direction.
Why Is Axsome (AXSM) Down 6.6% Since Last Earnings Report?
12:31pm, Wednesday, 25'th Mar 2026
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?
Critical Contrast: PTC Therapeutics (NASDAQ:PTCT) & Axsome Therapeutics (NASDAQ:AXSM)
02:56am, Monday, 23'rd Mar 2026
PTC Therapeutics (NASDAQ: PTCT - Get Free Report) and Axsome Therapeutics (NASDAQ: AXSM - Get Free Report) are both mid-cap medical companies, but which is the superior stock? We will contrast the two
This New $7 Million Bet Targets a CNS Drug Maker With Phase 3 Trial Underway and 27% Stock Gain
11:37am, Wednesday, 18'th Mar 2026
Superstring Capital Management purchased 37,433 shares of Axsome Therapeutics in the fourth quarter. The quarter-end position value was $6.84 million, representing a new holding in Axsome Therapeutics
AXSM's 2025 Revenue Surge Largely Driven by Auvelity: What's Ahead?
12:41pm, Friday, 13'th Mar 2026
Axsome's lead product, Auvelity, sales jumped 74% to $507M in 2025, fueling growth while other drugs added momentum.
Axsome Therapeutics, Inc. (AXSM) Presents at The Citizens Life Sciences Conference 2026 Transcript
03:52am, Friday, 13'th Mar 2026
Axsome Therapeutics, Inc. (AXSM) Presents at The Citizens Life Sciences Conference 2026 Transcript
Axsome Therapeutics, Inc. (AXSM) Presents at Leerink Global Healthcare Conference 2026 Transcript
07:40pm, Tuesday, 10'th Mar 2026
Axsome Therapeutics, Inc. (AXSM) Presents at Leerink Global Healthcare Conference 2026 Transcript
2 Under-the-Radar Stocks to Buy and Hold
01:13pm, Tuesday, 10'th Mar 2026
Axsome Therapeutics has an exciting late-stage pipeline. Madrigal Pharmaceuticals is looking to dominate a large market with significant unmet needs.
Axsome Therapeutics CEO Completes Planned $6 Million Options Sale Ahead of Pivotal FDA Decision
03:43pm, Monday, 09'th Mar 2026
32,410 shares were exercised and sold for a total transaction value of ~$6.0 million on February 2, 2026. After this transaction, Tabuteau directly held 7,229 shares and indirectly held 7,344,500 shar
Axsome Therapeutics to Participate in Upcoming Investor Conferences
07:00am, Wednesday, 25'th Feb 2026
NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today an
AXSM Q4 Loss Wider Than Expected, Revenues Surge Y/Y on Auvelity Sales
01:11pm, Tuesday, 24'th Feb 2026
Axsome misses Q4 estimates for earnings. Revenues jump 65% on strong Auvelity sales as well as other product sales and top estimates.
Axsome: Q4 Earnings Review: Solid Performance, But Pipeline May Be Overvalued
12:25pm, Monday, 23'rd Feb 2026
Axsome Therapeutics, Inc. delivered 66% full-year 2025 revenue growth to $638.5M, driven by Auvelity and Sunosi, but remains loss-making. Despite a robust pipeline and upcoming catalysts, I downgrade
Here's What Key Metrics Tell Us About Axsome (AXSM) Q4 Earnings
12:00pm, Monday, 23'rd Feb 2026
The headline numbers for Axsome (AXSM) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estima
Axsome Therapeutics (AXSM) Reports Q4 Loss, Tops Revenue Estimates
11:35am, Monday, 23'rd Feb 2026
Axsome Therapeutics (AXSM) came out with a quarterly loss of $0.71 per share versus the Zacks Consensus Estimate of a loss of $0.7. This compares to a loss of $0.96 per share a year ago.
